A Double-Blind, Randomized, Placebo-Controlled, Single-Center, Flexible Titration Study Evaluating the Efficacy of Solriamfetol in Treating Fatigue and Cognitive Symptoms in Adults Aged 18-65 Years With a Diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Latest Information Update: 07 Feb 2024
At a glance
- Drugs Solriamfetol (Primary)
- Indications Chronic fatigue syndrome; Encephalomyelitis
- Focus Therapeutic Use
- 07 Feb 2024 Status changed from recruiting to active, no longer recruiting.
- 31 Jan 2024 Planned End Date changed from 1 Feb 2024 to 1 May 2024.
- 31 Jan 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Mar 2024.